<DOC>
	<DOC>NCT00251888</DOC>
	<brief_summary>Search of maximum tolerated irinotecan dose in association with cisplatin and pelvic radiotherapy in patients with an advanced cervix cancer.</brief_summary>
	<brief_title>CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto</brief_title>
	<detailed_description>To determine the maximum and the recommended tolerated dose of irinotecan with increasing doses associated with weekly cisplatin and combinated with pelvic radiotherapy in patients with an advanced cervix cancer, IIB-IVA FIGO stage.</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically proven primitive epidermoid or andenocarcinoma Cervix FIGO stage IIB (obviously parameter attack), III or IVA No previous chemotherapy nor radiotherapy Patient for whom a radiochemotherapy is envisaged as first intention treatmentof her cervix carcinoma PS ECOG &lt; 2 Life expectancy &gt; 12 weeks Written consent given Other malignant cervix tumor histology Visceral remotly metastasis Other malignant tumor since 5 years, except spino or basocellular treaten and cured cancer Anormal labs values Peripheric neuropathy CTC &gt; 2 Auditory loss &gt; 2 Cardiopathy Inflammatory digestive pathology Evolutive infection Other experimental concommitant treatment Lacting or pregnant women</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>cervix cancer</keyword>
	<keyword>advanced cervix cancer</keyword>
	<keyword>radiochemotherapy</keyword>
	<keyword>pelvic radiotherapy</keyword>
	<keyword>campto</keyword>
	<keyword>cisplatin</keyword>
	<keyword>irinotecan</keyword>
	<keyword>cisplatyl</keyword>
	<keyword>maximum dose search</keyword>
</DOC>